XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Collaborations - Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Collaboration Revenue        
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax
Operating expenses:        
Research and development $ 63,239 $ 36,810 $ 150,942 $ 99,973
General and administrative 20,765 12,591 59,466 44,040
Total operating expenses 84,004 49,401 210,408 144,013
Incyte        
Collaboration Revenue        
Upfront payments 4,400 4,371 12,968 12,912
Reimbursement revenue 943 1,547 3,603 4,248
Milestones 0 3,479 1,000 5,980
Other 0 0 0 0
Total collaboration revenue 5,343 9,397 17,571 23,140
Operating expenses:        
Research and development 0 0 0 24
General and administrative 0 0 0 0
Total operating expenses 0 0 0 24
Revenue recognized in the period 4,400 4,371 12,968 12,912
Lilly        
Collaboration Revenue        
Upfront payments 4,038 789 5,310 8,270
Reimbursement revenue 194 847 698 3,543
Milestones 0 0 0 0
Other 0 0 0 0
Total collaboration revenue 4,232 1,636 6,008 11,813
Operating expenses:        
Research and development 0 0 0 0
General and administrative 0 0 0 0
Total operating expenses 0 0 0 0
Revenue recognized in the period 4,038 789 5,310 8,270
Gilead        
Collaboration Revenue        
Upfront payments 0 0 1,207 0
Reimbursement revenue 0 0 0 0
Milestones 0 0 0 0
Other 0 0 0 0
Total collaboration revenue 0 0 1,207 0
Operating expenses:        
Research and development 0 0 0 0
General and administrative 0 0 0 0
Total operating expenses 0 0 0 0
Revenue recognized in the period 0 0 1,207 0
Other        
Collaboration Revenue        
Upfront payments 0 0 0 0
Reimbursement revenue 0 0 0 0
Milestones 2,197 0 2,197 0
Other 0 0 10 55
Total collaboration revenue 2,197 0 2,207 55
Operating expenses:        
Research and development 0 0 0 0
General and administrative 0 0 0 0
Total operating expenses 0 0 0 0
Revenue recognized in the period 0 0 0 0
Collaboration Agreement        
Collaboration Revenue        
Upfront payments 8,438 5,160 19,485 21,182
Reimbursement revenue 1,137 2,394 4,301 7,791
Milestones 2,197 3,479 3,197 5,980
Other 0 0 10 55
Total collaboration revenue 11,772 11,033 26,993 35,008
Operating expenses:        
Research and development 0 0 0 24
General and administrative 0 0 0 0
Total operating expenses 0 0 0 24
Revenue recognized in the period $ 8,438 $ 5,160 $ 19,485 $ 21,182